Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc. (Nasdaq: CARTA) is a late clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases. Headquartered in Frederick, Maryland, the company leverages proprietary mRNA technology and manufacturing platforms to introduce mRNA into cells to provide… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Cartesian Therapeutics, Inc. does
In the company’s own words
Cartesian Therapeutics, Inc. (Nasdaq: CARTA) is a late clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases. Headquartered in Frederick, Maryland, the company leverages proprietary mRNA technology and manufacturing platforms to introduce mRNA into cells to provide therapeutic effects to patients suffering from various autoimmune conditions. Unlike DNA-based approaches, the company's mRNA modifications degrade naturally over time without integrating into the cell's genetic material, enabling therapies designed to be dosed repeatedly like conventional drugs and administered in outpatient settings without requiring pre-treatment chemotherapy.
The company's lead product candidate, Descartes-08, is an autologous CAR-T cell therapy targeting B-cell maturation antigen (BCMA) currently in clinical development for generalized myasthenia gravis (MG), myositis including dermatomyositis and antisynthetase syndrome, and juvenile dermatomyositis. Descartes-08 has received Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation from the FDA for MG treatment, as well as Rare Pediatric Disease Designation for juvenile dermatomyositis. The company has administered Descartes-08 to over 100 patients across various trials as of December 31, 2025, with clinical data demonstrating deep and durable benefits through 12 months without observed product-related cytokine release syndrome, neurotoxicity, or serious infections. In May 2025, the company initiated its Phase 3 AURORA trial in approximately 100 patients with acetylcholine receptor antibody-positive MG, with FDA agreement on the trial design through the Special Protocol Assessment process.
Cartesian maintains wholly-owned internal manufacturing and research and development capabilities at its cGMP-compliant Frederick facility, designed to support current clinical needs and potential commercial manufacturing. The company's intellectual property portfolio includes seven issued patents worldwide with expiration dates ranging from 2040 to 2044, plus 24 pending patent applications. The company also holds legacy assets from its 2023 merger with Selecta Biosciences, including a substantial patent portfolio and the Sobi License Agreement for nanoencapsulated sirolimus plus pegadricase development. Additional key agreements include non-exclusive licenses with Biogen and the National Cancer Institute for mRNA CAR-T technology development.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- FREDERICK, MD
- Fiscal year end
- December
- CIK
- 1453687
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Cartesian Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Cartesian Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Cartesian Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Cartesian Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Cartesian Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”